ID   HIPK1_HUMAN             Reviewed;        1210 AA.
AC   Q86Z02; A6NJ34; O75125; Q5SQL2; Q5SQL4; Q5SQL5; Q8IYD7; Q8NDN5;
AC   Q8NEB6; Q8TBZ1;
DT   29-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   15-MAR-2017, entry version 142.
DE   RecName: Full=Homeodomain-interacting protein kinase 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Nuclear body-associated kinase 2;
GN   Name=HIPK1; Synonyms=KIAA0630, MYAK, NBAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Miyata Y.;
RT   "Molecular cloning of human HIPK1.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 318-1210 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 720-1210 (ISOFORMS 1/3/4).
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [7]
RP   FUNCTION, AND PHOSPHORYLATION BY JNK1.
RX   PubMed=12968034; DOI=10.1074/jbc.M213201200;
RA   Song J.J., Lee Y.J.;
RT   "Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1
RT   oligomerization.";
RL   J. Biol. Chem. 278:47245-47252(2003).
RN   [8]
RP   TISSUE SPECIFICITY, AND INTERACTION WITH DAXX.
RX   PubMed=12529400; DOI=10.1128/MCB.23.3.950-960.2003;
RA   Ecsedy J.A., Michaelson J.S., Leder P.;
RT   "Homeodomain-interacting protein kinase 1 modulates Daxx localization,
RT   phosphorylation, and transcriptional activity.";
RL   Mol. Cell. Biol. 23:950-960(2003).
RN   [9]
RP   INTERACTION WITH TP53, TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [10]
RP   FUNCTION, INTERACTION WITH DAB2IP AND MAP3K5, SUBCELLULAR LOCATION,
RP   SUMOYLATION AT LYS-25 AND LYS-1203, DESUMOYLATION MEDIATED BY TNF, AND
RP   MUTAGENESIS OF LYS-25; ASP-315; LYS-317; LYS-440; LYS-556 AND
RP   LYS-1203.
RX   PubMed=15701637; DOI=10.1074/jbc.M414262200;
RA   Li X., Zhang R., Luo D., Park S.-J., Wang Q., Kim Y., Min W.;
RT   "Tumor necrosis factor alpha-induced desumoylation and cytoplasmic
RT   translocation of homeodomain-interacting protein kinase 1 are critical
RT   for apoptosis signal-regulating kinase 1-JNK/p38 activation.";
RL   J. Biol. Chem. 280:15061-15070(2005).
RN   [11]
RP   FUNCTION IN ANTI-OXIDATIVE STRESS, INTERACTION WITH PARK7, SUBCELLULAR
RP   LOCATION, AND DEGRADATION BY PARK7.
RX   PubMed=16390825; DOI=10.1080/10715760500456847;
RA   Sekito A., Koide-Yoshida S., Niki T., Taira T., Iguchi-Ariga S.M.M.,
RA   Ariga H.;
RT   "DJ-1 interacts with HIPK1 and affects H2O2-induced cell death.";
RL   Free Radic. Res. 40:155-165(2006).
RN   [12]
RP   DESUMOYLATION BY SENP1, AND SUBCELLULAR LOCATION.
RX   PubMed=18219322; DOI=10.1038/sj.cdd.4402303;
RA   Li X., Luo Y., Yu L., Lin Y., Luo D., Zhang H., He Y., Kim Y.-O.,
RA   Kim Y., Tang S., Min W.;
RT   "SENP1 mediates TNF-induced desumoylation and cytoplasmic
RT   translocation of HIPK1 to enhance ASK1-dependent apoptosis.";
RL   Cell Death Differ. 15:739-750(2008).
RN   [13]
RP   FUNCTION AS MYB KINASE, INTERACTION WITH MYB, MUTAGENESIS OF LYS-219,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=19646965; DOI=10.1016/j.bbrc.2009.07.139;
RA   Matre V., Nordgaard O., Alm-Kristiansen A.H., Ledsaak M.,
RA   Gabrielsen O.S.;
RT   "HIPK1 interacts with c-Myb and modulates its activity through
RT   phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 388:150-154(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-872, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-967 AND SER-1200, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-25, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-25, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-310 AND VAL-1165.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in
CC       transcription regulation and TNF-mediated cellular apoptosis.
CC       Plays a role as a corepressor for homeodomain transcription
CC       factors. Phosphorylates DAXX and MYB. Phosphorylates DAXX in
CC       response to stress, and mediates its translocation from the
CC       nucleus to the cytoplasm. Inactivates MYB transcription factor
CC       activity by phosphorylation. Prevents MAP3K5-JNK activation in the
CC       absence of TNF. TNF triggers its translocation to the cytoplasm in
CC       response to stress stimuli, thus activating nuclear MAP3K5-JNK by
CC       derepression and promoting apoptosis. May be involved in anti-
CC       oxidative stress responses. Involved in the regulation of eye
CC       size, lens formation and retinal lamination during late
CC       embryogenesis. Promotes angiogenesis and to be involved in
CC       erythroid differentiation. May be involved in malignant squamous
CC       cell tumor formation. {ECO:0000269|PubMed:12702766,
CC       ECO:0000269|PubMed:12968034, ECO:0000269|PubMed:15701637,
CC       ECO:0000269|PubMed:16390825, ECO:0000269|PubMed:19646965}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with Nkx1-2, Nkx2-5, MYB, PARK7, DAXX and
CC       p53/TP53. Part of a cytoplasmic complex made of HIPK1, DAB2IP and
CC       MAP3K5 in response to TNF. This complex formation promotes MAP3K5-
CC       JNK activation and subsequent apoptosis.
CC       {ECO:0000269|PubMed:12529400, ECO:0000269|PubMed:12702766,
CC       ECO:0000269|PubMed:15701637, ECO:0000269|PubMed:16390825,
CC       ECO:0000269|PubMed:19646965}.
CC   -!- INTERACTION:
CC       Q13643:FHL3; NbExp=3; IntAct=EBI-692891, EBI-741101;
CC       P04637:TP53; NbExp=2; IntAct=EBI-692891, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Predominantly
CC       nuclear. Translocates from nucleus to cytoplasm in response to
CC       stress stimuli via SENP1-mediated desumoylation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=HIPK1-alpha;
CC         IsoId=Q86Z02-1; Sequence=Displayed;
CC       Name=2; Synonyms=HIPK1-beta;
CC         IsoId=Q86Z02-2; Sequence=VSP_013130, VSP_013131;
CC       Name=3;
CC         IsoId=Q86Z02-3; Sequence=VSP_013128;
CC       Name=4;
CC         IsoId=Q86Z02-4; Sequence=VSP_013127, VSP_013129;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with highest levels in
CC       skeletal muscle and heart. Overexpressed in breast cancer cell
CC       lines. Isoform 2 is highly expressed in testis.
CC       {ECO:0000269|PubMed:12529400, ECO:0000269|PubMed:12702766}.
CC   -!- PTM: Autophosphorylated. Phosphorylated and activated by JNK1.
CC       {ECO:0000269|PubMed:12968034}.
CC   -!- PTM: Degraded by PARK7 at the protein level.
CC   -!- PTM: Sumoylated. When conjugated it is directed to nuclear
CC       speckles. SENP1-mediated desumoylation is mediated by TNF in
CC       response to stress stimuli, triggering transient translocation
CC       from nucleus to cytoplasm. {ECO:0000269|PubMed:15701637,
CC       ECO:0000269|PubMed:18219322}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. HIPK subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB089957; BAC57075.1; -; mRNA.
DR   EMBL; AL731797; CAI22792.1; -; Genomic_DNA.
DR   EMBL; AL731797; CAI22793.1; -; Genomic_DNA.
DR   EMBL; AL731797; CAI22795.1; -; Genomic_DNA.
DR   EMBL; AL137856; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471122; EAW56590.1; -; Genomic_DNA.
DR   EMBL; BC028408; AAH28408.1; -; mRNA.
DR   EMBL; BC033012; AAH33012.1; -; mRNA.
DR   EMBL; BC036057; AAH36057.1; -; mRNA.
DR   EMBL; AL833829; CAD38689.1; -; mRNA.
DR   EMBL; AB014530; BAA31605.1; -; mRNA.
DR   CCDS; CCDS41370.1; -. [Q86Z02-3]
DR   CCDS; CCDS867.1; -. [Q86Z02-1]
DR   CCDS; CCDS868.1; -. [Q86Z02-2]
DR   CCDS; CCDS869.1; -. [Q86Z02-4]
DR   RefSeq; NP_689909.2; NM_152696.3. [Q86Z02-2]
DR   RefSeq; NP_852003.1; NM_181358.2. [Q86Z02-4]
DR   RefSeq; NP_938009.1; NM_198268.2. [Q86Z02-1]
DR   RefSeq; NP_938010.1; NM_198269.2. [Q86Z02-3]
DR   RefSeq; XP_005270669.1; XM_005270612.4. [Q86Z02-1]
DR   RefSeq; XP_005270670.1; XM_005270613.4. [Q86Z02-1]
DR   UniGene; Hs.532363; -.
DR   ProteinModelPortal; Q86Z02; -.
DR   SMR; Q86Z02; -.
DR   BioGrid; 128490; 16.
DR   IntAct; Q86Z02; 17.
DR   MINT; MINT-1187651; -.
DR   STRING; 9606.ENSP00000358571; -.
DR   BindingDB; Q86Z02; -.
DR   ChEMBL; CHEMBL5427; -.
DR   GuidetoPHARMACOLOGY; 2033; -.
DR   iPTMnet; Q86Z02; -.
DR   PhosphoSitePlus; Q86Z02; -.
DR   BioMuta; HIPK1; -.
DR   DMDM; 34395641; -.
DR   EPD; Q86Z02; -.
DR   MaxQB; Q86Z02; -.
DR   PaxDb; Q86Z02; -.
DR   PeptideAtlas; Q86Z02; -.
DR   PRIDE; Q86Z02; -.
DR   Ensembl; ENST00000340480; ENSP00000340956; ENSG00000163349. [Q86Z02-3]
DR   Ensembl; ENST00000369553; ENSP00000358566; ENSG00000163349. [Q86Z02-4]
DR   Ensembl; ENST00000369558; ENSP00000358571; ENSG00000163349. [Q86Z02-1]
DR   Ensembl; ENST00000369559; ENSP00000358572; ENSG00000163349. [Q86Z02-2]
DR   Ensembl; ENST00000426820; ENSP00000407442; ENSG00000163349. [Q86Z02-1]
DR   GeneID; 204851; -.
DR   KEGG; hsa:204851; -.
DR   UCSC; uc001eel.4; human. [Q86Z02-1]
DR   CTD; 204851; -.
DR   DisGeNET; 204851; -.
DR   GeneCards; HIPK1; -.
DR   HGNC; HGNC:19006; HIPK1.
DR   HPA; HPA016664; -.
DR   MIM; 608003; gene.
DR   neXtProt; NX_Q86Z02; -.
DR   OpenTargets; ENSG00000163349; -.
DR   PharmGKB; PA134897980; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   eggNOG; ENOG410XPET; LUCA.
DR   GeneTree; ENSGT00760000119032; -.
DR   HOVERGEN; HBG051908; -.
DR   InParanoid; Q86Z02; -.
DR   KO; K08826; -.
DR   OMA; TDWRNAH; -.
DR   OrthoDB; EOG091G0UMX; -.
DR   PhylomeDB; Q86Z02; -.
DR   TreeFam; TF105417; -.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q86Z02; -.
DR   ChiTaRS; HIPK1; human.
DR   GeneWiki; HIPK1; -.
DR   GenomeRNAi; 204851; -.
DR   PRO; PR:Q86Z02; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000163349; -.
DR   CleanEx; HS_HIPK1; -.
DR   ExpressionAtlas; Q86Z02; baseline and differential.
DR   Genevisible; Q86Z02; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0034333; P:adherens junction assembly; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060059; P:embryonic retina morphogenesis in camera-type eye; IEA:Ensembl.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001654; P:eye development; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0061072; P:iris morphogenesis; IEA:Ensembl.
DR   GO; GO:0060235; P:lens induction in camera-type eye; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0010842; P:retina layer formation; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   Isopeptide bond; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1   1210       Homeodomain-interacting protein kinase 1.
FT                                /FTId=PRO_0000085993.
FT   DOMAIN      190    518       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     196    204       ATP. {ECO:0000305}.
FT   REGION      885   1093       Interaction with TP53.
FT                                {ECO:0000269|PubMed:12702766}.
FT   REGION      891    998       Required for localization to nuclear
FT                                speckles. {ECO:0000250}.
FT   REGION      902    926       SUMO interaction motifs (SIM); required
FT                                for nuclear localization and kinase
FT                                activity. {ECO:0000250}.
FT   MOTIF       844    847       Nuclear localization signal 1 (NLS1).
FT                                {ECO:0000250}.
FT   ACT_SITE    315    315       Proton acceptor. {ECO:0000305}.
FT   BINDING     219    219       ATP. {ECO:0000305}.
FT   MOD_RES     872    872       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     967    967       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1200   1200       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     25     25       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   CROSSLNK     25     25       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK   1203   1203       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:15701637}.
FT   VAR_SEQ       1    394       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013127.
FT   VAR_SEQ       1    374       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013128.
FT   VAR_SEQ     395    399       ASEYD -> MVLMF (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013129.
FT   VAR_SEQ    1049   1075       NQQSSAAPTSQERSSNPAPRRQQAFVA -> VSAMGYCLLF
FT                                GPCTVVTFWRTLLLAGC (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013130.
FT   VAR_SEQ    1076   1210       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013131.
FT   VARIANT       6      6       Q -> R (in dbSNP:rs35324789).
FT                                /FTId=VAR_051626.
FT   VARIANT     310    310       G -> C (in dbSNP:rs34335651).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040546.
FT   VARIANT    1165   1165       L -> V. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046047.
FT   MUTAGEN      25     25       K->R: Reduced sumoylation and cytoplasmic
FT                                subcellular location. Impaired
FT                                sumoylation and cytoplasmic subcellular
FT                                location; when associated with R-317; R-
FT                                440; R-556 and R-1203.
FT                                {ECO:0000269|PubMed:15701637}.
FT   MUTAGEN     219    219       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19646965}.
FT   MUTAGEN     315    315       D->N: Loss of kinase activity and
FT                                impaired MAP3K5-JNK inactivation.
FT                                {ECO:0000269|PubMed:15701637}.
FT   MUTAGEN     317    317       K->R: Nuclear subcellular location.
FT                                Impaired sumoylation and cytoplasmic
FT                                subcellular location; when associated
FT                                with R-25; R-440; R-556 and R-1203.
FT                                {ECO:0000269|PubMed:15701637}.
FT   MUTAGEN     440    440       K->R: Nuclear subcellular location.
FT                                Impaired sumoylation and cytoplasmic
FT                                subcellular location; when associated
FT                                with R-25; R-317; R-556 and R-1203.
FT                                {ECO:0000269|PubMed:15701637}.
FT   MUTAGEN     556    556       K->R: Nuclear subcellular location.
FT                                Impaired sumoylation and cytoplasmic
FT                                subcellular location; when associated
FT                                with R-25; R-317; R-440 and R-1203.
FT                                {ECO:0000269|PubMed:15701637}.
FT   MUTAGEN    1203   1203       K->R: Nuclear subcellular location.
FT                                Impaired sumoylation and cytoplasmic
FT                                subcellular location; when associated
FT                                with R-25; R-317; R-440 and R-556.
FT                                {ECO:0000269|PubMed:15701637}.
FT   CONFLICT    721    721       P -> Q (in Ref. 4; AAH33012).
FT                                {ECO:0000305}.
FT   CONFLICT    747    747       Missing (in Ref. 6; BAA31605).
FT                                {ECO:0000305}.
FT   CONFLICT    799    799       H -> Y (in Ref. 5; CAD38689).
FT                                {ECO:0000305}.
FT   CONFLICT   1054   1054       A -> V (in Ref. 4; AAH36057).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1210 AA;  130843 MW;  DB0BBFA6DF152909 CRC64;
     MASQLQVFSP PSVSSSAFCS AKKLKIEPSG WDVSGQSSND KYYTHSKTLP ATQGQANSSH
     QVANFNIPAY DQGLLLPAPA VEHIVVTAAD SSGSAATSTF QSSQTLTHRS NVSLLEPYQK
     CGLKRKSEEV DSNGSVQIIE EHPPLMLQNR TVVGAAATTT TVTTKSSSSS GEGDYQLVQH
     EILCSMTNSY EVLEFLGRGT FGQVAKCWKR STKEIVAIKI LKNHPSYARQ GQIEVSILSR
     LSSENADEYN FVRSYECFQH KNHTCLVFEM LEQNLYDFLK QNKFSPLPLK YIRPILQQVA
     TALMKLKSLG LIHADLKPEN IMLVDPVRQP YRVKVIDFGS ASHVSKAVCS TYLQSRYYRA
     PEIILGLPFC EAIDMWSLGC VIAELFLGWP LYPGASEYDQ IRYISQTQGL PAEYLLSAGT
     KTTRFFNRDP NLGYPLWRLK TPEEHELETG IKSKEARKYI FNCLDDMAQV NMSTDLEGTD
     MLAEKADRRE YIDLLKKMLT IDADKRITPL KTLNHQFVTM THLLDFPHSN HVKSCFQNME
     ICKRRVHMYD TVSQIKSPFT THVAPNTSTN LTMSFSNQLN TVHNQASVLA SSSTAAAATL
     SLANSDVSLL NYQSALYPSS AAPVPGVAQQ GVSLQPGTTQ ICTQTDPFQQ TFIVCPPAFQ
     TGLQATTKHS GFPVRMDNAV PIVPQAPAAQ PLQIQSGVLT QGSCTPLMVA TLHPQVATIT
     PQYAVPFTLS CAAGRPALVE QTAAVLQAWP GGTQQILLPS TWQQLPGVAL HNSVQPTAMI
     PEAMGSGQQL ADWRNAHSHG NQYSTIMQQP SLLTNHVTLA TAQPLNVGVA HVVRQQQSSS
     LPSKKNKQSA PVSSKSSLDV LPSQVYSLVG SSPLRTTSSY NSLVPVQDQH QPIIIPDTPS
     PPVSVITIRS DTDEEEDNKY KPSSSGLKPR SNVISYVTVN DSPDSDSSLS SPYSTDTLSA
     LRGNSGSVLE GPGRVVADGT GTRTIIVPPL KTQLGDCTVA TQASGLLSNK TKPVASVSGQ
     SSGCCITPTG YRAQRGGTSA AQPLNLSQNQ QSSAAPTSQE RSSNPAPRRQ QAFVAPLSQA
     PYTFQHGSPL HSTGHPHLAP APAHLPSQAH LYTYAAPTSA AALGSTSSIA HLFSPQGSSR
     HAAAYTTHPS TLVHQVPVSV GPSLLTSASV APAQYQHQFA TQSYIGSSRG STIYTGYPLS
     PTKISQYSYL
//
